1.	Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 74 Sponsor: NCI Protocol IDs: 080051, 08-C-0051, NCT00923910
2.	WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HaemaCBFWT102, Carreras 04/25f, NCT00153582
3.	WT1 Peptid Vaccination in Carcinomas Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HaemaCBFWT104, EU, NCT00153608
4.	Safety of Peptide Vaccination for Patients with Myelodysplastic Syndrome Phase: Phase I Type: Treatment Status: Active Age: 18 to 85 Sponsor: NHLBI Protocol IDs: 060062, 06-H-0062, NHLBI-06-H-0062, NCT00270452
5.	A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Autologous or Allogeneic Transplantation for AML, CML, ALL, MDS, and B Cell Malignancies Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: Pro00001360, NCT00672152